Cat. No. | Product name | CAS No. |
DC7668 |
CL-387785
Featured
CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370+/-120 pM; is able to overcome resistance caused by the T790M mutation on a functional level. |
194423-06-8 |
DC12292 |
Cl-amidine hydrochloride
Featured
Cl-amidine (hydrochloride) is a peptidylarginine deminase (PAD) inhibitor, with an IC50 5.9 μM for PAD4. |
1373232-26-8 |
DC9725 |
Cl-amidine
Featured
Cl-amidine is a cell-permeable compound that acts as a pan PAD inhibitor (IC50 = 0.8 µM, 6.2 µM and 5.9 µM for PAD1, PAD3, and PAD4, respectively) in enzymatic assays. |
1043444-18-3 |
DC9868 |
Clanfenur
Featured
Clanfenur is a substituted benzoylphenylurea and an analogue of the pesticide diflubenzuron with potential antineoplastic activity. |
51213-99-1 |
DC7387 |
Clemizole Hydrochloride
Featured
Clemizole is a H1 histamine receptor antagonist.Recently, researchers have identified that clemizole hydrochloride can inhibit NS4B's RNA binding and hepatitis C virus (HCV) replication. |
1163-36-6 |
DC8832 |
Clemizole (free base)
Featured
Clemizole is a H1 histamine receptor antagonist.Recently, researchers have identified that clemizole hydrochloride can inhibit NS4B's RNA binding and hepatitis C virus (HCV) replication. |
442-52-4 |
DC9380 |
Cleviprex
Featured
Clevidipine(Clevidipine) is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension. |
167221-71-8 |
DCAPI1085 |
Clevudine (Levovir)
Featured
Clevudine (Levovir) is an antiviral drug for the treatment of hepatitis B,showed potent activity against COVID-19(SARS-COV-2) . |
163252-36-6 |
DC21722 |
CLK-IN-T3
Featured
CLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110 nM for CLK1,2 and 3, respectively. |
2109805-56-1 |
DCAPI1428 |
Clofarabine
Featured
Clofarabine(Clolar; Clofarex) inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. IC50 Value: 65 nM Target: in vitro: Clofarabine is a second generation purine nucleoside analog with antineoplastic activity. It |
123318-82-1 |
DC7991 |
8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e](1,4)diazepine N-oxide
Featured
Clozapine N-oxide is a major metabolite of Clozapine noted to decrease SR-2A (5-HT2 serotonin receptor) density in vitro. |
34233-69-7 |
DC12714 |
CLP-290
Featured
CLP290 (CLP-290) is an orally acirtve small molecule K+-Cl- cotransporter isotype 2 (KCC2) activator, the carbamate prodrug of CLP257; In vivo co-treatment with morphine and oral CLP290 prevented membrane KCC2 downregulation in SDH neurons. Concurrently, co-treatment with CLP290 significantly mitigated MIH and acute administration of CLP257 in established MIH restored normal nociceptive behavior. |
1181083-81-7 |
DC9797 |
18-[4-(2,2-Difluoro-3-aza-1-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-1(12),4,6,8,10-pentaen-8-yl)phenyl]octadecyl-[2-(trimethylazaniumyl)ethoxy]phosphinate
Featured
CLR1501 is a synthetic analogs of the tumor-targeting agent alkylphosphocholine (APC), which is specifically attracted to cancer cells. |
1250963-36-0 |
DC10795 |
CM-272
Featured
CM-272 is a first-in-class reversible dual small molecule inhibitor against G9a and DNMTs in hematological malignancies. |
1846570-31-7 |
DC7605 |
CM346(Afobazole)
Featured
CM-346 increased the power of the low-frequency θ-rhythm (4.8–5.8 Hz) and the dominant activity peak (6.0–7.2 Hz) and decreased the spectral power in the 19–20 Hz band. |
173352-21-1 |
DC9803 |
CMP8
Featured
CMP8 is a high-affinity ligand that binds only to mutant ERLBD. |
851107-28-3 |
DC22512 |
CMPDA
Featured
CMPDA is a potent positive allosteric modulator of GluR2 receptors with EC50 of 45.4 and 63.4 nM at GluR2i and GluR2o respectively, in a calcium influx screening assays. |
380607-77-2 |
DC7761 |
Brincidofovir (CMX-001)
Featured
CMX001 (Brincidofovir; HDP-CDV) was developed as an orally active, lipophilic form of cidofovir (CDV); has enhanced activity in vitro and in vivo compared to CDV against certain herpesviruses, adenoviruses and orthopoxviruses.IC50 Value: 5.5 nM (EC50, in PDA at 7 dpi) [3]Target: anti-CMVCMX001 is currently in Phase II clinical studies for development as a therapeutic agent for human CMV, adenovirus and BK virus infections, as well as, for adverse events following smallpox vaccinations.in vitro: In PDA at 7 dpi, the CMX001 50% effective concentration (EC50) was 5.55 nM, the 50% cytotoxic concentration (CC50) was 184.6 nM, and the 50% selectivity index (SI50) was 33.3. The EC90 was 19.7 nM, the CC90 was 5,054 nM, and the SI90 was 256.1. In COS-7 cells, JCV replication was faster and the EC50 and EC90 were 18- and 37-fold higher than those in PDA, i.e., 0.1 μM and 0.74 μM (CC50, 0.67 μM; SI50, 6.7; CC90, 12.2 μM; SI90, 16.5) at 5 dpi [3].in vivo: CMX001 and CDV are equally efficacious at protecting mice from mortality following high ectromelia virus doses (10,000 x LD(50)) introduced by the intra-nasal route or small particle aerosol. Using CMX001 at a 10mg/kg dose followed by 2.5mg/kg doses every other-day for 14 days provided solid protection against mortality and weight loss following an intra-nasal challenge of (100-200) x LD(50) of ectromelia virus [1]. When CMX001 was administered orally to mice infected with HSV-1, mortality was reduced significantly (p≤0.001) with all three dose levels when treatments were initiated 24 h post viral inoculation. When treatments were started 48 h post viral inoculation, 5 and 2.5 mg/kg significantly reduced mortality (p≤ 0.001). If treatments were delayed until 72 h post viral inoculation, CMX001 did not reduce mortality or increase the mean day to death. When mice were infected intranasally with HSV-1 and treatments initiated 24 h post viral inoculation using CMX001 at 5 mg/kg or ACV at 100 mg/kg, virus replication in target organs was reduced by both CMX001 and ACV when compared to vehicle treated mice [2]. Toxicity: Diarrhea was the most common adverse event in patients receiving CMX001 at doses of 200 mg weekly or higher and was dose-limiting at 200 mg twice weekly. Myelosuppression and nephrotoxicity were not observed [4]. |
444805-28-1 |
DC12476 |
CN427
Featured
CN427 (CN-427) is novel BRD4 (BD1, 2) inhibitor with IC50 of 66 nM, MV4-11 viability IC50 of 1.1 uM.. |
|
DC10752 |
CNDAC HCl
Featured
CNDAC (DFP-10917; TAS-109) is an orally available deoxycytosine nucleoside analog with potential antineoplastic activity. |
134665-72-8 |
DC9799 |
CNDAC
Featured
CNDAC is the active component of sapacitabine. |
135598-68-4 |
DC10671 |
CNQX disodium salt
Featured
CNQX is a potent AMPA/kainate receptor antagonist. Also antagonist at glycine modulatory site on NMDA receptor complex. |
479347-85-8 |